AKS-452
Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
|
Medical response |
|
COVID-19 portal |
|
AKS-452 is a COVID-19 vaccine candidate developed by Akston Biosciences.[1][2]
References
- ^ "Anti-COVID19 AKS-452 – ACT Study (ACT)". ClinicalTrials.gov. 23 December 2020. NCT04681092. Retrieved 21 March 2021.
- ^ "A study to assess the safety and immunogenicity of Anti-COVID-19 AKS-452 vaccine for SARS-Сov-2 infection in Indian healthy subjects". ctri.nic.in. 11 October 2021. CTRI/2021/10/037269. Retrieved 11 October 2021.
Scholia has a profile for AKS-452 (Q110269780).
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Development | |||||||||||
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy |
| ||||||||||
Related | |||||||||||
|
Portals:
- Medicine
- Viruses
- COVID-19
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e